The dual-product regimen aims to optimize skin renewal by combining high-performance exfoliation with intensive cellular support. The RetaXome™ Treatment Pads, priced at $90, integrate a five-acid blend with retinal encapsulated in exosomes, a delivery method designed to stimulate collagen production while mitigating the irritation typically associated with retinoid use. The pads also incorporate Oligopeptide-10 to address blemish-related inflammation.
Complementing the pads, the $160 CÉLTHERA™ cream features a proprietary exosome-delivered vegan Epidermal Growth Factor, known as ExoEGF™, alongside NAD+ support to bolster cellular energy. CEO Keith O'Briant stated that the system reflects an evolution in addressing biological aging processes by leveraging advanced delivery systems. The products are currently available through a network of 6,000 professional practices globally and via the company’s website. This rollout supports the brand's 'Tomorrow's Skin Starts Tonight' campaign, which emphasizes the efficacy of nighttime interventions for skin health.
Comments (0)
No comments yet. Be the first!